Your MS winter safety toolkit
By Sylvia Leonard The cold season can make daily life especially challenging for people living with a disability. Weather-related limitations can present barriers…
ECTRIMS 2015 Highlights and General Impressions, Part II
Welcome back to my ECTRIMS 2015 recap. In the previous post I covered some of the crucial research being undertaken to further understand…
After the campaign comes action: Hopes for our new government
In a few hours, we will know the results of the federal election. After 78 days of intense campaigning, more than 66,000 polling…
ECTRIMS 2015 Highlights and General Impressions, Part I
Now that the dust from this year’s ECTRIMS meeting has finally settled, I’ve had the chance to sit back and reflect on my…
Why I Muck: Kim Moran
By Kim Moran My whole life I’ve prided myself on my independence. I’ve set goals and accomplished them. I’ve worked hard. It wasn’t…
Ocrelizumab marks an important milestone in research and treatment for progressive MS
Over 20 years ago, the first disease modifying therapy was approved in Canada for relapsing remitting MS, and since then we have seen…
Encouraging results presented at ECTRIMS Late Breaking News session
Perhaps the most anticipated session at ECTRIMS is “Late Breaking News”, which features a selection of exciting and newly released clinical trial results…
What is MS?
Canada has one of the highest rates of multiple sclerosis (MS) in the world, with an estimated 77,000 Canadians living with the disease. While it is most often diagnosed in young adults aged 20 to 49, younger children and older adults are also diagnosed with the disease.